Business Context and Reporting Period
Company: Alterity Therapeutics Limited (a development stage enterprise)
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Reporting Date: October 21, 2025
Purpose: Submission of the Notice of Annual General Meeting and Proxy Form (Exhibit 99.1) for incorporation by reference into Registration Statements on Form S-8 and Form F-3.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document serves as a procedural filing to distribute meeting notices rather than a financial report.
Material Changes
No material financial changes or operational updates are disclosed in this specific filing text.
Guidance, Outlook, and Risks
Management Commentary: None provided in this text.
Outlook: Not applicable.
Risks and Contingencies: Not disclosed in this text.
Unusual Items: The filing confirms the company is a development stage enterprise.
Investor Verification Checklist
- Verify the details of the Annual General Meeting in the attached Exhibit 99.1 (Notice of Annual General Meeting/Proxy Form).
- Confirm the status of the referenced Registration Statements (Form S-8 and Form F-3) for potential equity offerings.
- Review the most recent Form 20-F or quarterly reports for actual financial performance data, as this 6-K contains none.